ArticleMolecular therapy oncolytics2022

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity.

Edward Z Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.